Onyx Seeks Suitors After Rejecting Amgen’s Bid
July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Most Recent Videos
Was the DNC Hack Preventable?
46:31 - Eric O'Neill, Carbon Black's national security strategist, discusses how to respond to government hacks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)